- 专利标题： Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
-
申请号： US17778374申请日： 2020-11-20
-
公开(公告)号： US20230190922A1公开(公告)日： 2023-06-22
- 发明人: Henning Lauterbach , Maria Hinterberger , José Medina Echeverz , Matthias Habjan , Jürgen Hausmann , Markus Kalla
- 申请人： Bavarian Nordic A/S
- 申请人地址： DK Hellerup
- 专利权人： Bavarian Nordic A/S
- 当前专利权人： Bavarian Nordic A/S
- 当前专利权人地址： DK Hellerup
- 优先权： EP 210369.5 2019.11.20 EP 193706.7 2020.08.31
- 国际申请： PCT/EP2020/082926 2020.11.20
- 进入国家日期： 2022-05-19
- 主分类号： A61K39/285
- IPC分类号： A61K39/285 ; A61P37/04 ; A61K39/00 ; A61K9/00
摘要：
The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen (“TAA”) as well as 4-1BBL and/or CD40L and can be administered to a subject in any suitable manner, including by intravenous and/or intratumoral administration.
信息查询
